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Melania Cruciani1, Fabiana Rizzo1, Raffaele Calogero4, Roland Brosch3 & Eliana M. Coccia1
Modern strategies to develop vaccines against Mycobacterium tuberculosis (Mtb) aim to improve 
the current Bacillus Calmette-Guerin (BCG) vaccine or to attenuate the virulence of Mtb vaccine 
candidates. In the present study, the impact of wild type or mutated region of difference 1 (RD1) 
variants on the immunogenicity of Mtb and BCG recombinants was investigated in human primary 
dendritic cells (DC). A comparative analysis of transcriptome, signalling pathway activation, 
maturation, apoptosis, cytokine production and capacity to promote Th1 responses demonstrated 
that DC sense quantitative and qualitative differences in the expression of RD1-encoded factors—
ESAT6 and CFP10—within BCG or Mtb backgrounds. Expansion of IFN-γ producing T cells was 
promoted by BCG::RD1-challenged DC, as compared to their BCG-infected counterparts. Although 
Mtb recombinants acted as a strong Th-1 promoting stimulus, even with RD1 deletion, the 
attenuated Mtb strain carrying a C-terminus truncated ESAT-6 elicited a robust Th1 promoting 
phenotype in DC. Collectively, these studies indicate a necessary but not sufficient role for the RD1 
locus in promoting DC immune-regulatory functions. Additional mycobacterial factors are likely 
required to endow DC with a high Th1 polarizing capacity, a desirable attribute for a successful 
control of Mtb infection.
Tuberculosis (TB) remains one of the principal leading causes of death worldwide accounting for 9 
million new cases and about 1.5 million deaths each year1. The attenuated Mycobacterium bovis—bacil-
lus Calmette-Guerin (BCG)—is the only currently available vaccine targeted against TB. Because BCG 
provides limited and variable efficacy against the pulmonary form of the disease and has an unknown 
impact on protection of latently infected individuals, there is a urgent unmet need to develop new TB 
vaccines2. Novel genomic technologies have identified significant differences between Mycobacterium 
tuberculosis (Mtb) and BCG genomes that have furthered the development of numerous live attenuated 
recombinant strains with vaccine potential. The main genetic modification involved in the attenuation 
of the vaccine strain BCG is the deletion of the so-called genomic region of difference 1 (RD1)3, which 
is required for full virulence of Mtb. Indeed, the RD1 encodes two strong immunogenic antigens and 
virulence factors—the 6-kDa early secreted antigenic target (ESAT-6) and the 10-kDa culture filtrate 
protein (CFP-10)4—as well as several structural components of the ESAT-6 secretion system (ESX)-1 
type VII secretion system, which is responsible for ESAT-6 and CFP-10 secretion5,6.
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Several TB vaccination strategies are based either on improvements in BCG immunogenicity or on 
attenuation of Mtb virulence through insertion, mutation or deletion of this locus. When integrated 
into the BCG genome, the extended RD1 region improved the ability of BCG to protect against dis-
semination of TB in mouse and guinea pig models7. On the other hand, one of the most promising 
Mtb-based live vaccines (MTBVAC, NCT 02013245), which is currently in clinical trial, does not secrete 
the RD1-encoded factors and has acquired an attenuated phenotype without impairment of the immu-
nogenic potential8. The importance of the RD1 region in TB immunopathology resides in the crucial role 
that RD1-encoded factors play in controlling host-pathogen interactions. For instance, in macrophages, 
RD1- encoded molecules rupture the phagosomal membrane-bound compartment allowing the bacte-
rium to get access to the host cytosol. Bacterial products sensed inside the cytosol elicit cell death9–12, 
promote inflammasome activation with the related production of interleukin (IL)-1β and IL-1813,14 and, 
at the same time, become target of cytosolic components of the ubiquitin-mediated autophagy pathway15. 
A more complex link between RD1 and the control of the autophagic flux was recently identified by 
our group in human dendritic cells (DC)16. In this setting, we demonstrated that the autophagy block 
induced by RD1-encoded ESX-1 secretion system was overcome by a treatment with the autophagy 
inducer, rapamycin, which further induced IL-12 production and, in turn, strengthened the capacity of 
DC to expand a T helper (Th)1-oriented response.
Given the central role of human DC in orchestrating vaccine-induced immunity, an understanding 
of the DC-specific innate responses triggered by Mtb or BCG vaccine candidates will be critical for the 
design of efficient vaccine strategies. Thus, we sought to investigate how infection with BCG and Mtb 
recombinant strains, complemented with or deleted in the RD1 locus, or expressing mutated variants 
of the ESAT-6/CFP-10 complex, would impact DC functions. These studies revealed the capacity of DC 
to sense quantitative and qualitative differences among the Mtb and BCG recombinants, and highlight 
a necessary but not sufficient role for the RD1 locus in promoting DC immune-regulatory functions.
Results
Transcriptome analysis of DC challenged with BCG and Mtb recombinant strains. To inves-
tigate whether the RD1 locus and specifically the ESX-1 secretion system may impact the global gene 
expression profile in DC, a comparative microarray analysis was performed in primary human DC infected 
with parental Mtb or Mtb and BCG recombinant strains, expressing the RD1 region (MtbΔ RD1::RD1 
and BCG::RD1, respectively) or lacking the RD1 genetic locus (MtbΔ RD1::B412 and BCG::B412, respec-
tively) (for further details on strain characteristics and virulence see Supplementary Table S1). Total 
RNA was isolated, hybridized on the HumanHT-12 v4 Expression BeadChips (Illumina) and analyzed 
with the oneChannelGUI Bioconductor package17. Among the significantly expressed genes, the top up- 
and down-regulated transcripts with a minimum fold change of 2.5 were selected for further analysis 
(Fig. 1). Data set analysis revealed that DC infection with either wild type (wt) Mtb or MtbΔ RD1::RD1 
(recombinant strain carrying the extended RD1 locus as the parental Mtb) up-regulated the transcription 
of 215 genes in DC, whereas infection with MtbΔ RD1::B412 (recombinant strain deleted in the RD1 
region) up-regulated ~100 genes. Conversely, BCG::RD1 (recombinant strain containing the extended 
RD1 region) and BCG::B412 (recombinant strain containing the empty vector pYUB412) induced the 
expression of a lower number of genes (~60) as compared to Mtb strains; also a small number of tran-
scripts (~20) was found to be down-regulated in all experimental conditions. The differentially expressed 
genes were associated primarily with three pathways: immune cell trafficking, inflammatory response 
and IFN signaling (Fig.  2). Specific RD1-dependent gene signatures, common to both Mtb and BCG 
strains or specifically regulated only by Mtb, were identified and a hierarchical clustering analysis of 
this gene set is shown in Fig.  1. Transcripts that were RD1-regulated in both bacterial backgrounds 
were predominantly associated with inflammatory and immune cell trafficking pathways (Table  1A), 
including: IL1B, an important mediator of the inflammatory response; chemokine C-C motif ligand 20 
(CCL20), a chemotactic factor that attracts immature DC with a role in mucosal immunity against Mtb 
and other bacteria18; signal transducer and activator of transcription-4 (STAT4), a transcription fac-
tor induced by inflammatory stimuli and many pathogens contributing to the Th1 polarization19; CXC 
family ligand-8 (CXCL8, also called IL-8), a chemokine involved in the recruitment of neutrophils and 
T cells in the lung during Mtb infection20 and regulator of G-protein signaling 1 (RGS1), a member of 
the G-protein-coupled receptor family principally regulating chemokine and chemokine receptors and, 
in turn, orchestrating immune cell trafficking during responses to exogenous or infectious agents21,22. 
Interestingly, among the cellular genes induced in response to Mtb and BCG recombinant strains car-
rying RD1, the induction of IL23p19, which might cooperate with IL-1β and other cytokines in driving 
the Th17 response, was also observed23,24 (see below for further details).
With regard to the specific Mtb-induced RD1-dependent specific gene signature, transcripts belong-
ing to type I IFN and inflammation-related signaling were over-represented (Table 1B), indicating that 
Mtb infection of DC modulated the amplitude of the inflammatory responses compared to BCG, spe-
cifically inducing numerous well characterized type I IFN-stimulated genes (ISGs), including ISG20, 
IFN-induced protein with tetratricopeptide repeats 3 (IFIT3), 2′-5′-oligoadenylate synthetase-like pro-
tein (OASL), indolemine 2,3 dioxygenase-1 (IDO1), IL27p28, CXCL11, and pro-inflammatory cytokines 
such as tumor necrosis factor (TNF)-α , IL29 and IL6.
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To validate the transcriptome analysis data, quantitative real time PCR experiments were conducted 
in DC infected with Mtb and BCG recombinants. A robust induction of IFNB1 and IL29 (also known 
as IFNL1) was observed in DC infected with either wt Mtb or MtbΔ RD1::RD1 (Fig. 3) and correlated 
with the gene expression data demonstrating ISG up-regulation (Fig. 2 and Table 1B). Interestingly, the 
Figure 1. Transcriptome analysis of DC challenged with BCG and Mtb recombinants. Hierarchical 
clustering of genes differentially expressed in DC challenged for 8 h with parental Mtb, MtbΔRD1::RD1, 
MtbΔRD1::B412, BCG::RD1 or BCG::B412. The values in grey indicate that the expression of the gene was 
not significantly different in respect to not infected cells (Ctrl).
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levels of IL23p19 and IL27p28, two subunits of IL-12 family members, were also strongly induced in 
response to Mtb expressing RD1-encoded factors, whereas RD1 inserted in the BCG backbone stimulated 
the expression of IL23p19 only, thus confirming the results of gene expression profiling (Figs  1–3 and 
Table 1A). This observation prompted us to extend our analysis to other subunits of the heterodimeric 
cytokines IL-23 and IL-27: IL12B (also known as IL12p40) that pairs with IL23p19 to constitute IL-23, 
and EBI3 that associates with IL27p28 to form IL-2725. Expression of both IL12p40 and EBI3 subunits 
was induced by RD1 in the Mtb background, as occurs in response to Mtb infection (Supplementary 
Fig. S1). In contrast, BCG reconstituted with RD1 induced the expression of IL12p40, whereas the EBI3 
transcript was reduced in DC infected with BCG:: RD1(Supplementary Fig. S1).
Providing that RD1-encoded factors were shown to influence the signaling pathways leading to 
cytokine gene expression in Mtb infected cells26, we investigated in DC challenged with Mtb and BCG 
recombinants the intracellular activation of Mitogen-activated protein kinase (MAPK) and Nuclear 
Factor (NF)-kB, both involved in the transcriptional regulation of TNF and IL-12 family members 
(Fig. 4). A robust phosphorylation of MAPK, namely p38 and p44/42 (ERK1/2), was observed 3 h after 
infection with both wt Mtb or MtbΔ RD1::RD1 as compared to MtbΔ RD1::B412, which displayed a 
lower capacity to stimulate their activation. A fainter level of MAPK phosphorylated forms was found 
in total cell extracts derived from both BCG::RD1 and BCG::B412 infected DC. This activation profile 
mirrors that of the down-stream NF-kB p65 phosphorylation. In addition, the phosphorylation of IFN 
regulatory factor 3 (IRF3), master regulator of type I IFN and IL29 gene expression27,28, was also analyzed 
(Fig. 4). Infection with wt Mtb, MtbΔ RD1::RD1 and, slightly, MtbΔ RD1::B412, stimulated IRF3 phos-
phorylation, while minor modifications were detected in DC infected with BCG recombinants providing 
evidences for the IRF3-dependent transcriptional induction of IFNB1 and IL29 genes shown in Fig. 3.
Collectively, these data demonstrate that the RD1 locus confers to Mtb and BCG a differential capac-
ity to modulate the expression of IL-12 and IFN family members.
Different induction of pro-inflammatory cytokines in DC infected with BCG and Mtb recom-
binants. To correlate gene expression profile with secretion data, the presence of pro-inflammatory 
cytokines was analyzed in DC culture supernatants infected with the Mtb or BCG RD1 recombi-
nants, as well as variants expressing selected mutations in ESAT-6 and CFP-10 (for details about Mtb 
and BCG recombinants see Supplementary Table S1). As predicted by the gene expression data, the 
reintroduction of the entire RD1 locus into the BCG background conferred to infected-DC the abil-
ity to release IL-23 (Fig.  5A); importantly, IL-23 release was abrogated by a single point mutation 
in ESAT-6 (BCG::RD1-ESAT6G45T), or by a deletion of 12 amino acids at the ESAT-6 C-terminus 
(BCG::RD1-ESAT6Δ 84-95). In contrast, IL-23 production was sustained in all Mtb-infected cells, 
regardless of deletion or mutation in RD1 (Fig. 5A).
The analysis of cytokine release was extended to IL-12, which together with IL-23, promotes the 
expansion of IFN-γ producing cells29–31. Strikingly, IL-12 production was not detected in DC infected 
with BCG or BCG recombinants containing the entire RD1 region or carrying point mutation 
(BCG::RD1-ESAT6G45T) or deletion (BCG::RD1-ESAT6Δ 84-95) in ESAT-6 (Fig.  5B). Conversely, 
IL-12 was produced by all DC cultures infected with either wt or recombinant Mtb strains. However, 
Figure 2. Transcriptional signature of DC challenged with BCG and Mtb recombinants. Transcriptional 
signature of DC arranged by using Ingenuity Pathway Analysis for the genes modulated by RD1 locus in 
both BCG and Mtb backgrounds (A) or induced by RD1 region expressed within a Mtb-background only 
(B). Induced genes are represented in red, while repressed ones are shown in green.
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the release of IL-12 was higher after infection with Mtb strains containing an intact RD1 region, sug-
gesting that other factors, in addition to RD1, contribute to IL-12 production. When expression of the 
pro-inflammatory cytokines TNF-α and IL-1β was examined, a clear dependence on RD1 was observed 
for both BCG and Mtb recombinants (Fig. 5C,D). BCG::RD1 strongly enhanced the capacity of infected 
DC to release IL-1β , whereas the deletion of the entire RD1 locus or the specific mutation of ESAT-6 
and CFP-10 genes impaired both TNF-α and IL-1β secretion, regardless of the bacterial background 
(Fig. 5C,D). Thus, it is likely that the complex gene regulation driven in DC by RD1 alone or in combi-
nation with other mycobacterial factors, might be converted into a specific cytokine milieu controlling 
the immune response against mycobacteria or recombinant vaccine candidates.
Effect of Mtb and BCG recombinant strain infection on DC maturation and apoptosis. Next 
the capacity of Mtb and BCG RD1-recombinant strains to modulate DC phenotype upon infection 
Gene symbol Gene name Gene ID1
(A) RD1-dependent genes in both BCG and Mtb backgrounds
chemokine (C-C motif) ligand 20 6364
Interleukin 1, beta 3553
Regulator of G-protein signaling 1 5996
Interleukin 8 (chemokine (C-X-C motif) 
ligand 8) 3576
Interleukin 23, alpha subunit p19 51561
Signal transducer and activator of 
transcription 4 6775
Forkhead box Q1 94234
Nuclear transcription factor, X-box 
binding-like 1 152518
Adenosine A3 receptor 140
(B) RD1-dependent genes in Mtb background only
Interleukin 29 (Interferon, lambda 1) 282618
Chemokine (C-X-C motif) ligand 11 6373
Interleukin 6 3569
Tumor necrosis factor 7124
Chemokine (C-C motif) ligand 3-like 1 6349
Interferon stimulated exonuclease gene 
20 kDa 3669
Interferon, beta 1 3456
Interferon-induced protein with 
tetratricopeptide repeats 3 3437
Indoleamine 2,3-dioxygenase 1 3620
2’–5’-oligoadenylate synthetase-like 8638
Interleukin 27 246778
GTP cyclohydrolase 1 2643
Frequently rearranged in advanced T-cell 
lymphomas 2 23401
Ring finger protein 125, E3 ubiquitin 
protein ligase 54941
Tumor necrosis factor receptor 
superfamily member 25 8718
PML-RARA regulated adaptor molecule 1 84106
Table 1.  Selected top up- and down-regulated genes. 1http://www.ncbi.nlm.nih.gov/gene/  
Selected top up- (in red) and down-regulated (in green) genes showing RD1 dependence in both Mtb 
and BCG backgrounds. (A) Selected top up- (in red) and down-regulated (in green) genes showing RD1 
dependence in Mtb background only (B).
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was evaluated by flow cytometric measurement of co-stimulatory molecule cluster of differentiation 
(CD)86, the activation marker CD38, the MHC-II molecule HLA-DR and the maturation marker CD83 
(Fig.  6). DC challenge with wt or mutated Mtb strains induced expression of all the above markers, 
and MtbΔ RD1::RD1 generated the most robust maturation profile. Conversely, BCG recombinants also 
promoted DC maturation, but to a lower extent, suggesting again that the maturation process requires 
in addition to RD1, other Mtb-specific factors that are not present in BCG.
We next determined whether infection with Mtb and BCG recombinants affected DC apoptosis (Fig. 7), 
by labeling DC with Annexin-V in combination with a fixable viability dye (FvDye)31. Both wt Mtb and 
MtbΔ RD1::RD1-infected DC displayed a strong apoptotic phenotype as shown by the enhanced percent-
age of both early (Annexin-V+/FvDye−) and late apoptotic cells (Annexin-V+/FvDye+); in contrast, the 
infection with Mtb lacking RD1 locus did not promote apoptosis in the infected DC (Fig. 7). An inter-
mediate apoptotic phenotype was observed after infection with both MtbΔ RD1::RD1-ESAT6Δ 84-95 
and MtbΔ RD1::RD1-Δ promCFP10 variant strains. In contrast, BCG recombinant strains showed no 
evidence of enhanced early or late apoptosis (Fig. 7), again indicating that DC apoptosis is regulated by 
both RD1-encoded factors and, additional as yet unidentified Mtb-encoded factors.
Differential expansion of Th1 response by DC challenged with Mtb and BCG recombinant 
strains. The capacity of DC infected with wt and recombinant Mtb and BCG strains to stimulate 
IFN-γ production by allogeneic CD4+ T cells was then investigated in a mixed leukocyte reaction (MLR) 
(Fig.  8). Infection with the BCG::RD1 strain doubled the capacity of DC to expand IFN-γ producing 
T cells, compared to BCG::B412 or BCG mutants carrying point mutation (BCG::RD1-ESAT6G45T) 
or deletion (BCG::RD1-ESAT6Δ 84-95) in ESAT-6. While a robust IFN-γ production was observed in 
MLR conducted with DC infected with all Mtb recombinants, the MtbΔ RD1::RD1-ESAT6Δ 84-95 and 
MtbΔ RD1::RD1 recombinant strains conferred to DC the strongest capacity to promote Th1 phenotype 
(Fig.  8). This result correlated well with the data on cytokine release, DC maturation and apoptotic 
phenotype elicited by MtbΔ RD1::RD1-ESAT6Δ 84-95, and demonstrates that the deletion of 12 amino 
acids at the C-terminus of ESAT-6 does not affect the capacity of Mtb to activate the immune functions 
of DC, in spite of a reduced virulence phenotype.
Figure 3. Validation of transcriptome data on IFNB1, IL29, IL23p19 and IL27p28 gene expression. 
Real-time RT-PCR analysis was conducted in untreated DC (Ctrl) or in DC infected for 8 h with wt Mtb or 
with the indicated Mtb and BCG strains to evaluate the expression of IFNB1 (A), IL29 (B), IL23p19 (C) and 
IL27p28 (D). All quantification data are normalized to the GAPDH level using the equation 2−ΔCt. For real-
time RT-PCR, the shown results were mean of 4 experiments performed with RNAs derived from a set of 
experiments independent than those used in the transcriptome studies. p-values: *≤ 0.03; **≤ 0.02; ***≤ 0.004; 
****≤ 0.001; *****≤ 0.04.
www.nature.com/scientificreports/
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Discussion
Advances in the understanding of the mechanisms underlying protection against human pathogens are 
crucial for the development of novel strategies for infection prevention and treatment. How host innate 
immunity instructs an adaptive immune response that protects against active disease by restricting Mtb 
replication and transmission in the majority of individuals, remains unknown.
In the present study, we focused on the effects of the Mtb-expressed RD1 locus on DC function, 
and observed that RD1-encoded factors differentially modulated the host immune response based on 
the genetic background in which they were expressed (Fig. 2 and Table 1). For example, analysis of DC 
transcriptome after Mtb infection identified a network of cytokine genes involved in the establishment 
of the inflammatory state, such as IL1B, IL8, and IL23p19, that were induced by RD1 irrespective of the 
BCG or Mtb backgrounds (Fig. 2A), whereas the expression of the IL27p28 subunit, IFNB1, IL29 and the 
related ISGs were stimulated only when DC were infected with Mtb carrying RD1 (Fig. 2B). This result 
is reminiscent of global transcriptional profiling performed in tissues derived from mice infected with 
either wt or ESX-1 mutant bacilli or in vitro infected macrophages, where host ESX-1 controlled genes 
were predominantly IFN-regulated32. Additional genes and pathways were modulated by infection with 
Mtb and BCG recombinant strains, and further molecular and functional characterization is required to 
understand their contribution to immune response driven by infected DC.
Transcriptional profiling data showing the dependence of IL1B and IL23p19 expression on RD1 
encoded factors were confirmed at the protein level; IL-1β and IL-23 were found in the supernatants of 
DC cultures infected with BCG or Mtb strains carrying the RD1 locus. TNF-α release was also induced 
in DC infected with both Mtb and BCG strains carrying the RD1 genetic locus. Conversely, the expres-
sion of IL-12 was strictly dependent on Mtb, even if deleted of RD1, while was absent in response to the 
infection with all BCG strains. The expression of IFN-β paralleled that of IL-12 since IFNB1 transcrip-
tion was consistently induced upon DC challenge with Mtb clones and particularly with MtbΔ RD1::RD1, 
whereas a weak transcriptional response was observed in response to all BCG recombinants irrespective 
of RD1 presence (our unpublished data).
This transcriptional profile well correlates with the activation of cellular signaling cascades, involving 
NF-kB and MAPK26,33,34. In particular, the activation of these pathways mainly induced in Mtb- rather 
Figure 4. Analysis of p38, p44/42 MAPK, NFKB p65 and IRF3 activation. The intracellular pathways 
involving the activations of p38, p44/42 MAPK (3 h post infection) and of NFKB p65 subunit, IRF3 
transcriptional factor (6 h post infection) were investigated by western blotting on whole cell extracts 
prepared from DC infected with wt Mtb or with the indicated Mtb and BCG strains. To detect the 
phosphorylated IRF3 isoforms (p-IRF3, upper panel), cell extracts were analyzed on an SDS-10% PAGE gel 
and subjected to immunoblot analysis with anti-IRF3 Ab, while a shorter electrophoretic run on an SDS-
10% PAGE gel was performed to analyze the relative levels of IRF3 content (lower panel). A representative 
experiment, out of 3 independent experiments performed, is shown.
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than BCG-infected DC was further amplified when the RD1 locus was present, thereby enhancing the 
expression of pro-inflammatory cytokines, such as TNF-α and IL-23. In addition, the data on IRF3 
modulation after the infection with wt Mtb and MtbΔ RD1::RD1 are reminiscent of our previous find-
ings showing that the transcription of IL12A (also known as IL12p35) subunit and of IFN-β1 via IRF3 
activation takes place only in Mtb-infected DC, while is poorly induced in BCG-stimulated cells, which 
are consequently less efficient in promoting a Th1-oriented response33,35.
Within this context, it is important to reconsider recent data showing the ability of Mtb-induced 
IFN-β to restrict IL-1β synthesis in infected macrophages by limiting both IL1B transcription36 and 
AIM2 inflammasome activation37. Indeed, in MtbΔ RD1::RD1-infected DC IL-1β production was similar 
or even higher than the levels found in BCG::RD1 challenged cells where IFN-β production was absent, 
suggesting that it is unlikely that Mtb exploits IFN-β to dampen IL-1β mediated inflammation, at least 
in human DC.
These results imply that different intracellular cytokine pathways may be activated depending on 
the presence or absence of RD1-encoded ESX-1 secretion system which, by acting on phagosomal 
permeabilization, may allow several mycobacterial factors to stimulate different intracellular signaling 
components, such as the DNA sensor IFI16/IFI204, TANK-binding kinase 1 (TBK)/IRF3, NLR family 
pyrin domain containing 3 (NLRP3) and caspase-132,38,39. This interesting aspect of Mtb-host interaction 
requires further in-depth analysis to identify mycobacterial components and/or mycobacterial inducible 
mechanisms that fine-tune the balance between pro- and anti-inflammatory cytokines40.
Together with the modulation of the extra-cellular cytokine milieu, which acts both locally and 
systemically on multiple target cells to tune host immune response against Mtb40, the acquisition of a 
mature phenotype, required for an efficient antigen presentation, is a crucial event of pathogen defense 
signaling occurring in DC to instruct T cell response. Concerning this aspect, we observed that RD1 
was inefficient in promoting full DC maturation when introduced in the BCG background, as com-
pared to the response induced by wt Mtb infection. Similarly, no apoptosis was observed in DC in 
response to the infection with BCG strains carrying or not the RD1 region. In the case of DC infec-
tion with Mtb recombinants, however, a strong apoptotic phenotype was found induced by wt Mtb 
and the reconstituted strain MtbΔ RD1::RD1, in which the RD1 locus was reintroduced. Nonetheless, 
MtbΔ RD1::RD1-ESAT6Δ 84-95 and MtbΔ RD1::RD1-Δ promCFP10 strains, both lacking the expression 
of a functional ESAT-6/CFP10 complex, promoted DC apoptosis although at different degrees, whereas 
infection with MtbΔ RD1::B412 did not.
Figure 5. BCG and Mtb RD1-recombinant strains as different inducers of pro-inflammatory cytokines 
along DC infection. DC were left untreated (Ctrl) or infected for 24 h with wt Mtb or with the indicated 
Mtb and BCG recombinant strains. IL-23 production was measured by ELISA (A). The secretion of IL-12 
(B), TNF-α (C) and IL-1β (D) was instead evaluated by Inflammatory Cytokine kit. The results represent 
means + SEM of 7 independent experiments. Significance was calculated by Student’s t-test for paired data. 
p-values: *≤ 0.05; **≤ 0.005; ***≤ 0.01; ****≤ 0.0002.
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These interesting piece of data revealed on one hand that in BCG background the RD1 reintroduc-
tion is not sufficient to properly stimulate an apoptotic phenotype in infected DC. On the other hand, 
our results showed also that when the RD1 locus was present in a Mtb backbone, even if partially 
mutated leading to an non-functional ESX1 activity (as for both MtbΔ RD1::RD1-Δ promCFP10 and 
MtbΔ RD1::RD1-ESAT6Δ 84-95 strains), apoptosis will still occur. This well fits with a hypothesis in 
which other Mtb strain specific factors cooperate with RD1-encoded proteins (not only ESAT-6 and 
CFP10) for cell death induction. In accordance, recent findings obtained in mouse macrophages sug-
gested that Mtb virulence influences the level of host cell death, while the balance of apoptosis and 
necrosis is controlled by other strain-specific characteristics41.
Among the Mtb strain specific factors it is important to acknowledge the influence of the three-gene 
operon containing espACD, whose regulation mediated by the two-component virulence regulation sys-
tem PhoP/PhoR regulon, may differ in some members of the Mtb complex. Three mutations affecting 
the PhoPR genes, impair the production of molecules—including ESAT-6—involved in pathogenicity of 
animal-adapted lineages, as Mycobacterium bovis42. Nevertheless, these strains acquired compensatory 
mutations—as the deletion of the region upstream espACD operon, namely RD8—that short-cut the 
PhoP and EspR-enhancer like sequence-dependent regulation of espACD operon, thus restoring ESAT-6 
secretion42.
Nonetheless, it has been also described that the deletion of the RD8 region, which mainly occurs in 
the majority of nonpathogenic species, may cause a lowered ESX-1 activity, since the secretory func-
tion of this system is dependent on the EspA and EspC mycobacterial proteins43. Providing that the 
RD1-encoded ESX1 locus is present in both pathogenic and nonpathogenic species, it is conceivable 
that ESX-1 per se does not play a direct role but it may be a prerequisite for Mtb virulence while EspA 
represents a major determinant of ESX-1-mediated virulence43. Based on these observations, it is likely 
that the short EspR-enhancer like sequence present in BCG44 may limit the expression of ESAT-6 and 
CFP-10 heterodimer in BCG::RD1 recombinant as compared to that present in wt Mtb, thus contributing 
to a specific host-pathogen interaction and leading to a defined cytokine profile, a poor DC maturation 
and a reduced apoptotic phenotype of infected DC.
Another important issue, emerging from this comparative analysis is that all Mtb recombinants pos-
sess the capacity to expand a Th1 population producing IFN-γ , which may be dependent on both the 
cytokine milieu released by Mtb-infected DC—IL-12, IFN-β and IL-23—and the Mtb wide antigen port-
folio. Among Mtb specific antigens, the RD1-encoded factors significantly enhanced the capacity of BCG 
Figure 6. DC maturation in response to infection with Mtb and BCG strains. DC were left untreated 
(Ctrl) or infected for 24 h with parental Mtb or Mtb and BCG strains engineered in the RD1 locus. 
Expression of indicated molecules was calculated in 7 independent experiments using the MFI after the 
subtraction of the values of the isotype Ab controls. MFI value for each individual experiment is shown and 
data are reported as the MFI mean ± SEM. Statistical significance was determined by Student’s t-test for 
paired data. p-values: *≤ 0.00003; **≤ 0.007; ***≤ 0.003.
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to stimulate in DC a Th1-promoting phenotype. The expansion of an IFN-γ producing Th1 population 
still represents an important correlate of vaccine-induced immunity – although recently debated45,46—
since IFN-γ production potentiates macrophage killing, enhances phagosome maturation and increases 
lysosomal delivery of mycobacteria by activating autophagy. In addition, the extreme susceptibility of 
individuals bearing deficiencies in the IFN-γ and IL-12 pathways to develop TB47 argues that IFN-γ 
production by CD4+ T cells serves as a protective immune marker.
In conclusion, the results of this study further highlight the importance of examining the interac-
tion of Mtb with human DC to provide important pre-clinical information about the immunogenic-
ity of potential vaccine candidates. The ability of RD1-encoded factors to elicit different nuances of 
DC response depending on the BCG or Mtb backgrounds where they are inserted, sheds light on the 
existence of a fine interplay between host- and bacterial-regulated events controlling immune response, 
whose understanding would open new perspectives in therapeutic and vaccine strategies against Mtb.
Methods
Antibodies (Abs) and other reagents. Monoclonal Abs specific for CD1a, CD14, CD38, CD86, 
CD83, HLA-DR, IgG1, IgG2a (BD Bioscience), Annexin-V (Abcam) and FvDye eFluor R780 (eBi-
oscience) were used as direct conjugates to Fluorescein isothiocyanate (FITC), Phycoerythrin or 
Allophycocyanin-7 as needed.
Figure 7. Different impact of BCG and Mtb mutants on DC apoptosis. DC were left untreated (Ctrl), 
or infected for 24 h with wt Mtb or Mtb and BCG recombinant strains. Apoptosis was assessed by FACS 
analysis through Annexin-V and FvDye staining. A representative experiment, out of 5 independent 
experiments performed, is shown. Numbers in the dot plots correspond to the percentage of cells in each 
quadrant.
Figure 8. Sufficient but not necessary role of ESX-1 secretion system in eliciting a protective Th1 
response. Control DC (Ctrl) and DC challenged for 24 h with the parental Mtb or with the indicated 
Mtb and BCG mutant strains were co-cultured with allogeneic CD4+ T for 5 days. IFN-γ production was 
evaluated by ELISA in harvested supernatants. The results shown represent means + SEM of 6 independent 
experiments. Significance was calculated by Student’s t-test for paired data, p-value: *≤ 0.04.
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DC preparation and infection. Istituto Superiore di Sanità Review Board approved the present 
research project (CE/13/387). DC were prepared as previously described35. Briefly, DC were generated 
by culturing CD14+monocytes with GM-CSF (50 ng/ml) and IL-4 (1000 U/ml) (R&D Systems) for 5 
days at 0.5 × 106 cells/ml in RPMI 1640 (Lonza), supplemented with L-glutamine (2 mM) and 15% Fetal 
Bovine Serum (FBS) (Lonza). At day 5 the cells were tested for their differentiation status by evaluat-
ing CD1a expression (> 90% CD1a+) and lack of CD14 (> 95% CD14−). Before infection, the medium 
was replaced with RPMI without antibiotics and supplemented with L-glutamine (2 mM) and 15% FBS. 
Cytokine deprivation did not affect DC survival rate, which was > 90%.
DC cultures were then infected with a multiplicity of infection (MOI) of 1 bacteria/cell as previously 
described31 and internalization assays demonstrated that all different recombinant strains used in this 
study were taken-up by DC similarly to the parental Mtb (Supplementary Fig. S2).
Bacteria description and preparation. Mycobacterial strains used in this study are listed in 
Supplementary Table S1. In particular, all Mtb recombinants were engineered from the mutant strain 
Mtb H37RvΔ RD1 (MtbΔ RD1)4 containing the deletion of the RD1 region48. All BCG recombinants 
were engineered from BCG Pasteur49. The pRD1-2F9 cosmid6,7, carrying the extended RD1 locus, was 
integrated into H37Rv∆RD1 strain4 and BCG to generate Mtb∆RD1::RD1 and BCG::RD1 strains while 
the control constructs MtbΔ RD1::B412 and BCG::B412 contained the empty vector pYUB412.
For construction of Mtb- and BCG- ESAT6∆84-85 expressing strains, a modified version of the 
pRD1-2F9 cosmid harboring the last 12 codons of the ESAT-6-encoding gene replaced by a SpeI 
restriction site was used6. For Mtb∆RD1::RD1-∆promCFP10, a pRD1-2F9 cosmid variant, carrying a 
122-bp in frame deletion immediately upstream the CFP-10-encoding gene, was employed6. Finally, the 
BCG::RD1-ESAT6G45T was obtained by using a pRD1-2F9 variant, into which a point mutation (G to 
T) had been introduced into the ESAT-6-encoding gene esxA, resulting in the substitution of the Gly45 
residue with a Thr residue in the modified ESAT-6 protein50.
For each recombinant strain, a qualitative evaluation of ESAT-6 expression and secretion has been 
conducted on bacterial cell lysate and culture filtrate by western blotting (see below for details) to ensure 
the stability of the desired mutations (Supplementary Fig. S3).
Mtb H37Rv (ATCC 27294; American Type Culture Collection) was grown, as previ-
ously described35. Recombinant strains Mtb∆RD1::RD1, Mtb∆RD1::B412, Mtb∆RD1::RD1-
∆promCFP10, Mtb∆RD1::RD1-ESAT6∆84-95, BCG::RD1, BCG::B412, BCG::RD1-ESAT6∆84-95 and 
BCG::RD1-ESAT6G45T were grown as specified above with the addition of hygromicin (50 μ g/ml) 
(Sigma) as selection6,50–52.
Logarithmically growing cultures were centrifuged at 800 rpm for 10 min to eliminate clumped myco-
bacteria and then washed three times in RPMI 1640. Mycobacteria were re-suspended in RPMI 1640 
containing 15% FBS and then stored at − 80 °C until use. Bacterial frozen vials were thawed and bacterial 
viability was determined by counting the number of colony forming units (CFU). All bacterial prepara-
tions were tested for endotoxin contamination (< 1 Endotoxin U/ml) by the Limulus lysate assay (Lonza).
CFU assay. DC were infected with recombinant Mtb and BCG strains at MOI 1. Five h after infection, 
cell cultures were extensively washed with RPMI 1640. DC were then centrifuged at 150 × g for 10 min 
to selectively spin down cells while extracellular bacteria remained in the supernatants. Cells were lysed 
and CFU enumerated as previously described31.
ESAT-6 expression. Parental and recombinant mycobacterial strains were grown in 20 ml of Sauton 
liquid medium at 37 °C for 6 days. Bacteria were harvested by centrifugation and culture filtrates, recov-
ered after filtration through 0.2 μ m pore-size filters, were concentrated using a filter with a 3-kDa cut-
off (Centricon; Millipore). The mycobacterial pellets were washed twice and suspended in Tris 20 mM 
(pH 7.5) containing protease inhibitors (Roche Diagnostics GmbH). Cells were broken by shaking with 
106-μ m acid washed-glass beads (Sigma) for 8 min at speed 30 in a tissue lyser apparatus (Qiagen). The 
whole-cell lysates were then centrifuged at 14,000 rpm for 30 min to remove bacterial cell debris.
Bacterial supernatant and whole-cell lysate were separated on a 15% PAGE Bis-Tris gel and elec-
troblotted onto nitrocellulose membranes (GE Healthcare, Freiburg, Germany). Immunoblot analysis 
was carried out with mouse ESAT-6 monoclonal Abs (Hyb 76-8; Statens Serum Institute, Copenhagen, 
Denmark) and detection achieved using horseradish peroxidase-conjugate anti-mouse secondary Abs. 
Finally, blots were visualized with Enhanced Chemiluminescence plus kit (GE Healthcare).
Once concentrated, bacterial supernatant were separated on a 15% PAGE Bis-Tris gel and elec-
troblotted onto nitrocellulose membranes (GE Healthcare, Freiburg, Germany). Immunoblot analysis 
was carried out with mouse ESAT-6 monoclonal Abs (Hyb 76-8; Statens Serum Institute, Copenhagen, 
Denmark) and detection achieved using horseradish peroxidase-conjugate anti-mouse secondary Abs. 
Finally, blots were visualized with Enhanced Chemiluminescence plus kit (GE Healthcare).
RNA extraction and Real-time PCR quantification. RNA was extracted from control or 
8 h-infected DC, obtained from 4 independent healthy donors, with RNeasy kit (Qiagen Inc.) according 
to the manufacturer’s instructions. A phenol/chloroform extraction was performed to inactivate residual 
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mycobacterial particles. Reverse transcriptions and quantitative PCR assays were performed as previ-
ously described33. The primers used for IFNB1, IL29, IL23p19, IL27p28, IL12p40, EBI3 and GAPDH 
were previously described53,54. Transcript expression was normalized to the GAPDH level using the 
Equation 2−ΔCt; the values are means ± SD of triplicate determinations.
Transcriptomic analysis. DC cultures from 2 healthy donors were infected for 8 h with parental 
Mtb and the indicated Mtb and BCG recombinants. RNAs were extracted with mirVana isolation kit 
(Ambion, Life Technologies) according to the manufacturer’s instructions. RNA quantification and integ-
rity was inspected by bioanalyzer analysis (Agilent Technologies). cRNAs were generated and hybridized 
on HumanHT-12 v4 Expression BeadChips according to the Illumina TotalPrep RNA Amplification 
Protocol (Illumina). The chips were then scanned with the Illumina scanner to generate the digitized 
image data files. Data were analyzed using the BeadStudio software package to generate a probe-level 
profile without background subtraction. Data were further analyzed with oneChannelGUI bioconductor 
package17. Specifically data were normalized by loess55 and the number of genes evaluated was reduced 
by applying an interquartile filter (IQR > 0.25) to remove the non significant probe sets (i.e. not expressed 
and those not changing)56 (http://www.bepress.com/bioconductor/). To assess differential expression, 
we used an empirical Bayes method57 together with a false discovery rate correction of the p-value58. 
Hierarchical clustering (ST, Euclidean distance, average clustering) was performed using TMEV 4.8 soft-
ware (http://www.tigr.org/software/). The genes annotated in the Ingenuity knowledge database were 
analyzed using the data-mining tool IPA 7.0 (www.ingenuity.com). Each treatment was subjected to IPA 
4.0 analysis, and subsequently, the results were subjected to a comparative analysis to identify functional 
classes associated with differentially expressed genes in response to different treatments. Gene expression 
data have been deposited in the NCBI’s Gene Expression Omnibus (GEO, http: http://www.ncbi.nlm.nih.
gov/geo, GEO Series accession number GSE62423), according to the MIAME standards.
Flow cytometry analysis. Cells (105) were washed once in PBS containing 2% FBS and incu-
bated with monoclonal Abs at 4 °C for 30 min. After washing the cells were fixed in 4% formaldehyde 
(PanreacQuimica) before analysis on a FACSCan using CellQuest software (Becton Dickinson). A total 
of 20,000 cells were analyzed per sample. The viable DC were gated by forward and side scatter and then 
the expression of cell surface molecules was evaluated using the median fluorescence intensity (MFI) 
after subtraction of the values of the isotype Ab controls. Only cells comprised in viable cell gate were 
considered for the analysis.
Immunoblot analysis. Western blots were performed as previously described33. Briefly, 25 μ g of total 
cell extracts were separated by 10% SDS-PAGE gel and blotted onto nitrocellulose membranes.
Blots were incubated with rabbit polyclonal anti-IRF3 and rabbit polyclonal anti-NFkB p65 (Santa 
Cruz Biotechnology, Santa Cruz, CA), rabbit polyclonal anti-phospho-NFkB p65 (Ser536), rabbit poly-
clonal anti-p44/42 MAPK, rabbit polyclonal anti-phospho-p44/42 MAPK (Thr202/Tyr204), rabbit poly-
clonal anti-phospho-p38 MAPK (Thr180/Tyr182) (Cell Signaling Technology, Danvers, MA) and mouse 
monoclonal anti-p38 MAPK (R&D Systems, Minneapolis, MN) Abs. Detection was achieved using 
horseradish peroxidase-conjugate secondary Abs anti-mouse and anti-rabbit (Jackson Immunoresearch) 
and visualised with Enhanced Chemiluminescence plus (GE Healthcare). A ChemiDoc XRS (Bio-Rad 
Laboratories, Hercules, CA) was used to reveal the chemiluminescence.
Cytokine determination. Supernatants of DC cultures were harvested 24 h after infection, filtered 
(0.2 μ m) and stored at − 80 °C. The production of IL-12, TNF-α and IL-1β was then measured by human 
Inflammatory Cytokine kit (Cytometric Bead Array; BD Bioscience). IL-23 and IFN-γ release was instead 
assayed by ELISA (R&D Systems).
Apoptosis detection. Phosphatidylserine exposure and membrane integrity were analyzed by using 
Annexin V-FITC and FvDye according to manufacturing protocols. Twenty-four h post infection, DC 
were stained with FvDye and then labeled for 15 min with 5X Annexin V-FITC, as previously described31. 
Finally, the cells were fixed with formaldehyde 8% for 30 min before analysis on a FACSCanto (BD 
Bioscience). A total of 30,000 cells were analyzed per sample. Data were analyzed by FlowJo software 
(TreeStar Inc., Ashland, OR).
MLR experiment. MLR was conducted as previously described33. Briefly, CD4+ T cells were puri-
fied by indirect magnetic sorting with a CD4+ T-cell isolation kit (Miltenyi) from allogeneic PBMC. 
Immature DC and DC infected for 24 h with wild type Mtb or Mtb and BCG recombinant strains 
described previously were re-suspended in 10% FBS complete medium prior to co-culture with total 
CD4+ T cells. Supernatants from T cell/DC co-culture (ratio 10:1) were harvested at day 5 and analyzed 
for IFN-γ production.
Statistical analysis. Statistical analysis was calculated using a two-tailed Student’s t-test for paired 
data. A p value < 0.05 was considered statistically significant.
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